Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.
Status:
Completed
Trial end date:
2020-05-06
Target enrollment:
Participant gender:
Summary
A phase I, single-center, randomized, double-blind, placebo-controlled single dose escalation
study, and a positive-controlled multiple dose extension study to evaluate the safety,
tolerance, pharmacokinetics and immunogenicity of recombinant human albumin injection in
healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
First Hospital of Jilin University The First Hospital of Jilin University